Fibrosis in Systemic Sclerosis

Rheumatic Disease Clinics of North America

Volumn 34, Issue 1, 2008, Pages 115-143

  Varga, John A ^a   Trojanowska, Maria ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CHEMOKINE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 1; FRACTALKINE; GAMMA INTERFERON; INTEGRIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PROTEIN PARC; RANTES; SMAD1 PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR FLI 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNINDEXED DRUG;

BONE MARROW CELL; CLINICAL TRIAL; COLLAGEN SYNTHESIS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERICYTE; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SKIN FIBROSIS; STEM CELL; SYSTEMIC SCLEROSIS;

ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; HUMANS; MICE; PERICYTES; SCLERODERMA, SYSTEMIC;

EID: 40149092637     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.11.002     Document Type: Review

References (132)

1. Kraling B.M., Maul G.G., and Jimenez S.A. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 63 1 (1995) 48-56
2. Jelaska A., and Korn J.H. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43 10 (2000) 2230-2239
3. Davies C.A., Jeziorska M., Freemont A.J., et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37 2 (2006) 190-197 [Epub 2005 Dec 15]
4. Rudnicka L., Varga J., Christiano A.M., et al. Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by TGF-ß. J Clin Invest 93 4 (1994) 1709-1715
5. van der Slot A.J., Zuurmond A.M., Bardoel A.F., et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278 42 (2003) 40967-40972 [Epub 2003 Jul 24]
6. Gardner H., Shearstone J.R., Bandaru R., et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 54 6 (2006) 1961-1973
7. Whitfield M.L., Finlay D.R., Murray J.I., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100 21 (2003) 12319-12324
8. Asano Y., Czuwara-Ladykowska J., and Trojanowska M. TGF-beta regulates DNA-binding activity of transcription factor Fli1 by PCAF-dependent acetylation. J Biol Chem 282 48 (2007) 34672-34683
9. Wang Y., Fan P.S., and Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54 7 (2006) 2271-2279
10. Atamas S.P., Yurovsky V.V., Wise R., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42 6 (1999) 1168-1178
11. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 12 (2002) 1581-1586
12. Veeraraghavan S., Nicholson A.G., and Wells A.U. Lung fibrosis: new classifications and therapy. Curr Opin Rheumatol 13 6 (2001) 500-504
13. Fernandes F., Ramires F.J., Arteaga E., et al. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 9 4 (2003) 311-317
14. Varga J., and Abraham D.J. Systemic sclerosis: paradigm multisystem fibrosing disorder. J Clin Invest 117 3 (2007) 557-567
15. Varga J., and Bashey R.I. Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12 2-4 (1995) 187-199
16. Abraham D.J., Eckes B., Rajkumar V., et al. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9 2 (2007) 136-143
17. Tomasek J.J., Gabbiani G., Hinz B., et al. Myofibroblasts and mechanoregulation of connective tissue remodeling. Nat Rev Mol Cell Biol 3 5 (2002) 349-363
18. Rajkumar V.S., Howell K., Csiszar K., et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7 5 (2005) R1113-R1123 [Epub 2005 Jul 21]
19. Helmbold P., Fiedler E., Fischer M., et al. Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol 31 6 (2004) 431-440
20. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112 12 (2003) 1776-1784
21. Abe R., Donnelly S.C., Peng T., et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166 12 (2001) 7556-7562
22. Quan T.E., Cowper S., Wu S.P., et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36 4 (2004) 598-606
23. Kuwana M., Okazaki Y., Kodama H., et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74 5 (2003) 833-845
24. Bellini A., and Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 87 9 (2007) 858-870 [Epub 2007 Jul 2]
25. Abraham D.J., and Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26 11 (2005) 587-595
26. Varga J., and Trojanowska M. Molecular pathways as novel therapeutic targets in systemic sclerosis. Current Opin Rheumatol 19 6 (2007) 568-573
27. Ghosh A.K., and Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 213 3 (2007) 663-671
28. Dong C., Zhu S., Wang T., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99 6 (2002) 3908-3913
29. Asano Y., Ihn H., Yamane K., et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 113 2 (2004) 253-264
30. Ghosh A.K., Bhattacharyya S., and Varga J. The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279 46 (2004) 47455-47463 [Epub 2004 Sep 1]
31. Svegliati S., Cancello R., Sambo P., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280 43 (2005) 36474-36482 [Epub 2005 Aug 4]
32. Kubo M., Czuwara-Ladykowska J., Moussa O., et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163 2 (2003) 571-581
33. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 117 (2005) 69-80
34. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev 19 23 (2005) 2783-2810
35. Bhattacharyya S., Ghosh A.K., Pannu J., et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 52 4 (2005) 1248-1258
36. Ishida W., Mori Y., Lakos G., et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 126 8 (2006) 1733-1744 [Epub 2006 Jun 1]
37. Mori Y., Ishida W., Bhattacharyya S., et al. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 50 12 (2004) 4008-4021
38. Chen Y., Shi-wen X., Eastwood M., et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 54 4 (2006) 1309-1316
39. Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87 11 (2007) 1077-1091
40. Moustakas A., and Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 118 (2005) 3573-3584
41. Sato M., Shegogue D., Gore E.A., et al. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol 118 4 (2002) 704-711
42. Hayashida T., Decaestecker M., and Schnaper H.W. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta dependent responses in human mesangial cells. FASEB J 17 11 (2003) 1576-1578 [Epub 2003 Jun 17]
43. Hayashida T., Wu M., Pierce A., et al. MAP kinase activity necessary for TGF-ß stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. J Cell Sci 120 Pt 23 (2007) 4230-4240
44. Daniels C.E., Wilkes M.C., Edens M., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114 (2004) 1308-1316
45. Pannu J., Nakerakanti S., Smith E., et al. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 282 (2007) 10405-10413
46. Goumans M.J., Valdimarsdottir G., Itoh S., et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12 (2003) 817-828
47. Abe H., Matsubara T., Iehara N., et al. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 279 (2004) 14201-14206
48. Matsubara T., Abe H., Arai H., et al. Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Lab Invest 86 (2006) 357-368
49. Takahashi T., Abe H., Arai H., et al. Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem 280 (2005) 7100-7106
50. Pannu J., Gardner H., Shearstone J.R., et al. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: a model of scleroderma. Arthritis Rheum 54 (2006) 3011-3021
51. Holmes A., Abraham D.J., Chen Y., et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 278 (2003) 41728-41733
52. Chen S.J., Ning H., Ishida W., et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 281 (2006) 21183-21197
53. Yu J., de Belle I., Liang H., et al. Coactivating factors p300 and CBP are transcriptionally cross-regulated by Egr1 in prostate cells, leading to divergent responses. Mol Cell 15 (2004) 83-94
54. Cho S.J., Kang M.J., Homer R.J., et al. Role of early growth response-1 (Egr-1) in interleukin-13 induced inflammation and remodeling. J Biol Chem 281 (2006) 8161-8168
55. Czuwara-Ladykowska J., Shirasaki F., Jackers P., et al. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276 (2001) 20839-20848
56. Nakerakanti S.S., Kapanadze B., Yamasaki M., et al. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 281 (2006) 25259-25269
57. Ghosh A.K., Bhattacharyya S., Lakos G., et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50 (2004) 1305-1318
58. Cheng S., Afif H., Martel-Pelletier J., et al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 279 (2004) 22057-22065
59. Distler J.H., Jungel A., Huber L.C., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56 1 (2007) 311-322
60. Kolch W. Coordinating ERK/MAPK signaling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6 (2005) 827-837
61. Hayashida T., Poncelet A.C., Hubchak S.C., et al. TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 56 5 (1999) 1710-1720
62. Tourkina E., Gooz P., Pannu J., et al. Opposing effects of protein kinase C-alpha and protein kinase C-epsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 280 (2005) 13879-13887
63. Tan F.K. Autoantibodies against PDGF receptor in scleroderma. N Engl J Med 354 25 (2006) 2709-2711
64. Eckes B., Zigrino P., Kessler D., et al. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 19 (2000) 325-332
65. Asano Y., Ihn H., Yamane K., et al. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 175 (2005) 7708-7718
66. Asano Y., Ihn H., Yamane K., et al. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 164 (2004) 1275-1292
67. Asano Y., Ihn H., Yamane K., et al. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 168 (2006) 499-510
68. Mimura Y., Ihn H., Jinnin M., et al. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol 166 (2005) 1451-1463
69. Sato S., Nagaoka T., Hasegawa M., et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 27 1 (2000) 149-154
70. Igarashi A., Nashiro K., Kikuchi K., et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105 2 (1995) 280-284
71. Fonseca C., Lindahl G.E., Ponticos M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 357 12 (2007) 1210-1220
72. Leask A., and Abraham D.J. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 81 6 (2003) 355-363
73. Chujo S., Shirasaki F., Kawara S., et al. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 203 2 (2005) 447-456
74. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 8 3 (1997) 171-179
75. Mori Y, Hinchcliff M, Wu M, et al. Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp Cell Res 2008, in press.
76. Klareskog L., Gustafsson R., Scheynius A., et al. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33 10 (1990) 1534-1541
77. Ludwicka A., Ohba T., Trojanowska M., et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22 10 (1995) 1876-1883
78. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
79. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110 1 (2007) 237-241 [Eppub 2007 Mar 15]
80. Postlethwaite A.E., Holness M.A., Katai H., et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90 4 (1992) 1479-1485
81. Hasegawa M., Fujimoto M., Kikuchi K., et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24 (1997) 328-332
82. Sakkas L.I., Tourtellotte C., Berney S., et al. Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 6 5 (1999) 660-664
83. Salmon-Ehr V., Serpier H., Nawrocki B., et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132 7 (1996) 802-806
84. Fichtner-Feigl S., Fuss I.J., Young C.A., et al. Induction of IL-13 triggers TGF-beta1 dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 178 9 (2007) 5859-5870
85. Jinnin M., Ihn H., Yamane K., et al. Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 279 40 (2004) 41783-41791
86. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 140 4 (2006) 345-356
87. Yanaba K., Komura K., Kodera M., et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 65 1 (2006) 124-126
88. Reitamo S., Remitz A., Varga J., et al. Demonstration of interleukin-8 and autoantibodies to interleukin-8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 129 2 (1993) 189-193
89. Carulli M.T., Ong V.H., Ponticos M., et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 52 12 (2005) 3772-3782
90. Ferreira A.M., Takagawa S., Fresco R., et al. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 126 8 (2006) 1900-1908
91. Ong V.H., Evans L.A., Shiwen X., et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 48 7 (2003) 1979-1991
92. Prasse A., Pechkovsky D.V., Toews G.B., et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 56 5 (2007) 1685-1693
93. Pilewski J.M., Liu L., Henry A.C., et al. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 166 2 (2005) 399-407
94. Harrison N.K., Cambrey A.D., Myers A.R., et al. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Lond) 86 2 (1994) 141-148
95. Feghali C.A., and Wright T.M. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 42 7 (1999) 1451-1457
96. Yasuoka H., Zhou Z., Pilewski J.M., et al. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 169 5 (2006) 1633-1642
97. Jimenez S.A., Freundlich B., and Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74 3 (1984) 1112-1116
98. Duncan M.R., and Berman B. Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med 162 2 (1985) 516-527
99. Jaffe H.A., Gao Z., Mori Y., et al. Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene. Exp Lung Res 25 3 (1999) 199-215
100. Ghosh A.K., Yuan W., Mori Y., et al. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276 14 (2001) 11041-11048
101. Chizzolini C., Rezzonico R., Ribbens C., et al. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 41 11 (1998) 2039-2047
102. Freundlich B., Jimenez S.A., Steen V.D., et al. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. Arthritis Rheum 35 10 (1992) 1134-1142
103. Grassegger A., Schuler G., Hessenberger G., et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139 4 (1998) 639-648
104. Hunzelmann N., Anders S., Fierlbeck G., et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 133 5 (1997) 609-613
105. Trojanowska M. What did we learn by studying scleroderma fibroblasts?. Clin Exp Rheumatol 22 3 Suppl 33 (2004) S59-S63
106. Mimura Y., Ihn H., Jinnin M., et al. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 124 5 (2005) 886-892
107. Jun J.B., Kuechle M., Min J., et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 124 2 (2005) 298-303
108. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 49 2 (2008) 103-113
109. Yamane K., Ihn H., Kubo M., et al. Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts. Arthritis Rheum 46 9 (2002) 2421-2428
110. Kawakami T., Ihn H., Xu W., et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110 1 (1998) 47-51
111. Kubo M., Ihn H., Yamane K., et al. Up-regulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 29 12 (2002) 2558-2564
112. Mori Y., Chen S.J., and Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48 7 (2003) 1964-1978
113. Varga J. SSc and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 46 7 (2002) 1703-1713
114. Verrecchia F., Laboureau J., Verola O., et al. Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology (Oxford) 46 5 (2007) 833-841 [Epub 2007 Jan 25]
115. Ihn H., Yamane K., Asano Y., et al. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 45 2 (2006) 157-165 [Epub 2005 Nov 30]
116. Clark S.H. Animal models in scleroderma. Curr Rheumatol Rep 7 2 (2005) 150-155
117. Green M.C., Sweet H.O., and Bunker L.E. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82 3 (1976) 493-512
118. Bayle J., Fitch J., Jacobsen K., et al. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol (2007) [epub ahead of print]
119. Jimenez S.A., Millan A., and Bashey R.I. Scleroderma-like alterations in collagen metabolism occurring in the TSK (tight skin) mouse. Arthritis Rheum 27 2 (1984) 180-185
120. Baxter R.M., Crowell T.P., McCrann M.E., et al. Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents. Lab Invest 85 10 (2005) 1199-1209
121. Siracusa L.D., McGrath R., Ma Q., et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6 4 (1996) 300-313
122. Christner P.J., Peters J., Hawkins D., et al. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 38 12 (1995) 1791-1798
123. Yamamoto T., Takagawa S., Katayama I., et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112 4 (1999) 456-462
124. Lakos G., Melichian D., Wu M., et al. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 73 5 (2006) 224-237
125. Lakos G., Takagawa S., Chen S.J., et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165 1 (2004) 203-217
126. Lakos G., Takagawa S., and Varga J. Animal models of SSc. Methods Mol Med 102 (2004) 377-393
127. Zhang Y., and Gilliam A.C. Animal models for scleroderma: an update. Curr Rheumatol Rep 4 2 (2002) 150-162
128. Zhang Y., McCormick L.L., Desai S.R., et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168 6 (2002) 3088-3098
129. Ruzek M.C., Jha S., Ledbetter S., et al. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50 4 (2004) 1319-1331
130. Sonnylal S., Denton C.P., Zheng B., et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 56 (2007) 334-344
131. Denton C.P., Lindahl G.E., Khan K., et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II TGF-ß receptor. J Biol Chem 280 16 (2005) 16053-16065
132. Wynne T. Cellular and molecular mechanisms of fibrosis. J Pathol 214 2 (2008) 199-210